INTRODUCTION: Bisphosphonates are the most commonly used drugs for the prevention and treatment of osteoporosis. Although a recent FDA review of the results of clinical trials reported no clear link between bisphosphonates and serious or non-serious atrial fibrillation (AF), some epidemiologic studies have suggested an association between AF and bisphosphonates. METHODS: We conducted a meta-analysis of non-experimental studies to evaluate the risk of AF associated with bisphosphonates. Studies were identified by searching MEDLINE and EMBASE using a combination of the Medical Subject Headings and keywords. Our search was limited to English language articles. The pooled estimates of odds ratios (OR) as a measure of effect size were calculated using a random effects model. RESULTS: Seven eligible studies with 266,761 patients were identified: three cohort, three case-control, and one self-controlled case series. Bisphosphonate exposure was not associated with an increased risk of AF [pooled multivariate OR 1.04, 95% confidence interval (CI) 0.92-1.16] after adjusting for known risk factors. Moderate heterogeneity was noted (I-squared score = 62.8%). Stratified analyses by study design, cohort versus case-control studies, yielded similar results. Egger's and Begg's tests did not suggest an evidence of publication bias (P = 0.90, 1.00 respectively). No clear asymmetry was observed in the funnel plot analysis. Few studies compared risk between bisphosphonates or by dosing. CONCLUSIONS: Our study did not find an association between bisphosphonate exposure and AF. This finding is consistent with the FDA's statement.
INTRODUCTION:Bisphosphonates are the most commonly used drugs for the prevention and treatment of osteoporosis. Although a recent FDA review of the results of clinical trials reported no clear link between bisphosphonates and serious or non-serious atrial fibrillation (AF), some epidemiologic studies have suggested an association between AF and bisphosphonates. METHODS: We conducted a meta-analysis of non-experimental studies to evaluate the risk of AF associated with bisphosphonates. Studies were identified by searching MEDLINE and EMBASE using a combination of the Medical Subject Headings and keywords. Our search was limited to English language articles. The pooled estimates of odds ratios (OR) as a measure of effect size were calculated using a random effects model. RESULTS: Seven eligible studies with 266,761 patients were identified: three cohort, three case-control, and one self-controlled case series. Bisphosphonate exposure was not associated with an increased risk of AF [pooled multivariate OR 1.04, 95% confidence interval (CI) 0.92-1.16] after adjusting for known risk factors. Moderate heterogeneity was noted (I-squared score = 62.8%). Stratified analyses by study design, cohort versus case-control studies, yielded similar results. Egger's and Begg's tests did not suggest an evidence of publication bias (P = 0.90, 1.00 respectively). No clear asymmetry was observed in the funnel plot analysis. Few studies compared risk between bisphosphonates or by dosing. CONCLUSIONS: Our study did not find an association between bisphosphonate exposure and AF. This finding is consistent with the FDA's statement.
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: T Jared Bunch; Jeffrey L Anderson; Heidi T May; Joseph B Muhlestein; Benjamin D Horne; Brian G Crandall; J Peter Weiss; Donald L Lappé; Jeffrey S Osborn; John D Day Journal: Am J Cardiol Date: 2009-01-24 Impact factor: 2.778
Authors: Henrik Toft Sørensen; Steffen Christensen; Frank Mehnert; Lars Pedersen; Roland D Chapurlat; Steven R Cummings; John A Baron Journal: BMJ Date: 2008-03-11
Authors: Kenneth W Lyles; Cathleen S Colón-Emeric; Jay S Magaziner; Jonathan D Adachi; Carl F Pieper; Carlos Mautalen; Lars Hyldstrup; Chris Recknor; Lars Nordsletten; Kathy A Moore; Catherine Lavecchia; Jie Zhang; Peter Mesenbrink; Patricia K Hodgson; Ken Abrams; John J Orloff; Zebulun Horowitz; Erik Fink Eriksen; Steven Boonen Journal: N Engl J Med Date: 2007-09-17 Impact factor: 91.245
Authors: Kristin M D'Silva; Sara Jane Cromer; Elaine W Yu; Michael Fischer; Seoyoung C Kim Journal: J Bone Miner Res Date: 2020-11-02 Impact factor: 6.741
Authors: Dae Hyun Kim; James R Rogers; Lisa A Fulchino; Caroline A Kim; Daniel H Solomon; Seoyoung C Kim Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240